Abstract: The invention relates to a slaked lime composition containing Ca(OH)2 particles of platelet crystalline morphology, called platelets, said platelets having a diameter D, this being the diameter of the circle circumscribing the platelet, a thickness e and an aspect ratio given by the ratio of said diameter of the platelet-circumscribing circle to said thickness, said composition having a platelet content of between 50 and 100% relative to the sum of the Ca(OH)2 particles and said aspect ratio being between 10 and 300, and to its manufacturing process.

Abstract: This disclosure relates to a method for continuously and proportional adding of lime to a water flow through in a plant, wherein a number of slakers are used for batchwise slaking of burnt lime, and wherein lime slurry with a greater degree of fineness and prolonged sedimentation time is produced. A first slaker empties completely slaked and diluted lime slurry after the weight principle proportional to the water flow through of the plant, until a predetermined mass of slurry weight is left, which is used for mixing with a next batch. A second slaker, which is ready for its emptying sequence, starts emptying completely slaked and diluted lime slurry after the weight principle proportional to the water flow through of the plant, when the first slaker has finished emptying, until a predetermined mass of slurry weight is left, which is used for mixing with a next batch.

Abstract: A method includes operating a gas loading system with a source of one or more isotopes of hydrogen, a gas loading chamber containing a number of metallic nanoparticles, the metallic nanoparticles being selected to provide for a predetermined hydrogen cluster formation density, a vacuum system, and a valve system in communication with the gas loading chamber, the source of one or more isotopes of hydrogen and the vacuum system; providing the gas loading chamber with a first quantity of the one or more isotopes of hydrogen from the source of one or more isotopes of hydrogen; monitoring an operating temperature; and cycling a loading pressure of the gas loading chamber using the source of one or more isotopes of hydrogen in response to providing the gas loading chamber and monitoring the operating temperature.

Abstract: A titanium silicate variant named UPRM-5 was prepared using tetraethylammonium hydroxide as a structure-directing agent (SDA). Successful detemplation was achieved via ion exchange with NH4Cl. Effective functionalization was obtained after ion exchanging the detemplated material using SrCl2 and BaCl2. Adsorption of CO2 at 25° C. in Sr- and Ba-UPRM-5 materials activated at different temperatures. For low partial pressures, the observed CO2 adsorption capacities increased as follows: NH4-UPRM-5<Sr-UPRM-5<Ba-UPRM-5. Both the Sr- and Ba-UPRM-5 materials exhibited outstanding selectivity for CO2 over CH4, N2 and O2.

Abstract: The present invention provides multiple modalities for detecting LOX-1. More particularly, an imaging composition is provided that allows for the in vivo imaging of atherosclerotic plaque.

Abstract: Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent.

Abstract: The present invention herein provides, for instance, a stable isotope-labeled phenylalanine wherein a carbon atom of the phenyl group linked to an amino acid residue is 13C, 2 to 4 carbon atoms of the remaining 5 carbon atoms constituting the phenyl group are 12C atoms to which deuterium atoms are bonded, and the remaining carbon atoms are 13C atoms to which hydrogen atoms are linked, and a stable isotope-labeled tyrosine wherein a carbon atom of the phenyl group linked to an amino acid residue is 13C, the carbon atom bonded to the hydroxyl group (OH group) of the phenyl group is 12C or 13C, 2 to 4 carbon atoms of the remaining 4 carbon atoms constituting the phenyl group are 12C atoms to which deuterium atoms are bonded, and the remaining carbon atoms are 13C atoms to which hydrogen atoms are linked.

Abstract: Orally disintegrating tablets containing colored granules of a water-soluble sugar which give them a speckled appearance are described. The orally disintegrating tablets with speckled appearance are readily and easy identifiable by physicians, nurses and patients.

Abstract: An air treating composition for eliminating odors from air in combination with specific spray valve and actuator requirements and spray performance parameters providing maximum dispersion of the active component in the composition into the air is disclosed. The particles of the composition are small so that the active component is dispersed into air as a fine dispersion to provide more contact with odors and to provide quick absorption of odors. The particle size of the composition is controlled through the selection of valve and actuator dimensions. The air treating and odor eliminating composition of the invention includes water, a low molecular weight polyol, an emulsifier, and a propellant. The composition may also include additional adjuvants such as solvent(s), fragrance(s), corrosion inhibitor, pH adjustor and the like.

Abstract: The invention concerns preparations, particularly cosmetic or pharmaceutical/dermatological preparations, containing phenylbenzimidazole sulfonic acid (i.e. 2-phenylbenzimidazole-5-sulfonic acid) neutralised with basic amino acids such as arginine, lysine, ornithine and histidine so that the pH of the preparation can be at or below 7.0 without incurring crystallization of the phenylbenzimidazole sulfonic acid.

Abstract: The present application relates to organosilicones and compositions such as consumer products comprising such organosilicones, as well as processes for making and using such organosilicones and such compositions. Such compositions comprising such organosilicones are easier to formulate, and provide more economical and superior care benefits when compared to current silicone containing compositions.

Abstract: A hair cosmetic composition which gives a feeling of light-sliding smoothness and a not-heavy feeling of not-unruliness to hair. The hair cosmetic composition contains a both terminally long-chain alkylamino group-modified polyorganosiloxane having a viscosity at 25° C. of 1,000 to 5,000,000 mPas, represented by the formula: MDxD?yM wherein M is a siloxy unit represented by the formula: R1R22SiO0.5, D is a siloxy unit represented by the formula: R22SiO, and D? is a siloxy unit represented by the formula: R2R3SiO, where R1 is an alkyl group having 12 to 50 carbon atoms, R2 is a substituted or unsubstituted hydrocarbon group having 1 to 6 carbon atoms, R3 is 3-aminopropyl group and/or N-(2-aminoethyl)-3-aminopropyl group, x is a value of 1 to 2,000, and y is a value of 1 to 50.

Abstract: The invention relates to graftable polymers comprising biologically active agents and the use of such polymers in the manufacture of shaped articles, such as implantable medical devices and catheters. The graftable polymers are covalently grafted to a surface via one or more grafting moieties incorporated into the pharmaceutically-active graftable polymer. The coated articles of the invention can further comprise tie-coats, and the ratio of polymer:tie coat can be used to adjust the rate of drug elution.

Abstract: The present invention relates to the use of a particular type of adipose tissue derived mesenchymal stem cells (AD-MSCs), which exert immunosuppressive properties, in the manufacture of a pharmaceutical composition for the prevention and treatment of the graft-versus-host disease (GVHD) produced after allogeneic hematopoietic stem cell transplantation.

Abstract: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to treat obesity. One embedment of the present invention relates to the use of Lactobacillus rhamnosus CGMCC 1.3724 and/or Lactobacillus rhamnosus NCC 4007 for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.

Abstract: Provide a visceral fat reducing agent for reducing the diseases and conditions associated with the metabolic syndrome which represents a condition where various risk factors such as those for hypertension, hyperlipemia, glucose tolerance dysfunction, etc., have accumulated, or simply reducing an accumulation of visceral fat, wherein the effective ingredient of said visceral fat reducing agent includes fungus bodies of lactic bacteria, especially lactic bacteria belonging to the Lactobacillus sp. and Lactococcus sp. and/or cultures thereof, while also providing a beverage, food or feed containing said visceral fat reducing agent.

Abstract: There is provided an anti-cancer composition comprising an aquatic microbial extract, and there is more particularly provided an anti-cancer composition comprising a Bacillus sp. strain extract.

Abstract: A micronutrient dosage unit which comprises two or more micronutrients selected from vitamin A, vitamin B2, vitamin B6, vitamin B9, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, calcium, magnesium, zinc, boron and chromium in one or more specified ratios. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.

Abstract: Provided herein are methods for treating a subject suffering from phenylketonuria by administering a phenylalanine hydroxylase (“PAH”) and/or a phenylalanine ammonia lyase (“PAL”) to the subject under conditions effective to deliver the phenylalanine 4-hydroxylase and/or PAL to the subject's small intestine. Also provided are methods for increasing the therapeutic activity of a phenylalanine 4-hydroxylase by thiolating the phenylalanine 4-hydroxylase. In addition, provided are oral dosage forms that include a phenylalanine 4-hydroxylase and/or a PAL and an enteric coating.

Abstract: Stabilized angiogenin compositions and methods of preparing stabilized angiogenin compositions by immobilization on a lipid-based substrate, such as a phospholipid or Coenzyme-Q10, are disclosed.

Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.

Abstract: Compositions and methods for preventing, reducing or inhibiting immunologic disorders are provided. Suitable compositions include one or more LIGHT-HVEM antagonists. LIGHT-HVEM antagonists include compounds that inhibit, reduce, or block the biological activity or expression of LIGHT and/or HVEM. LIGHT-HVEM antagonists can reduce or inhibit the binding of LIGHT to HVEM, but do not significantly modulate the binding of LT? to LT?R. Suitable compositions include antibodies and antibody fragments, decoy polypeptides, small molecule inhibitors and inhibitory nucleic acids. Methods for using LIGHT-HVEM antagonists to reduce or inhibit T cell activation and survival are also provided. Therapeutic uses for LIGHT-HVEM antagonists to prevent or treat immunologic diseases and disorders including graft rejection, graft-versus-host disease, inflammatory immune responses, and autoimmune disorders are provided.

Abstract: The invention relates to purinergic (P2X) receptors, more specifically to P2X7 receptors, the generation of antibodies and the use of antibodies and immunogens that are capable of selectively binding to a non ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor, for the detection and treatment of disease conditions, especially cancer.

Abstract: Provided are a novel means for regulating inflammatory reactions by regulating the signaling in inflammatory responses caused by non-homeostatic cell death, specifically an anti-inflammatory agent comprising a substance that inhibits the expression of Mincle or the interaction of Mincle and SAP130 or FcR?, a screening method for a substance that regulates inflammatory reactions, comprising contacting Mincle or a fragment containing an extracellular region thereof and SAP130 in the presence and absence of a test substance, and comparing the degrees of the interaction of Mincle or the fragment thereof and SAP130 under the two conditions, a method of detecting non-homeostatic cell death, comprising measuring the amount of SAP130 in a sample collected from a subject animal, and the like.

Abstract: Methods and compositions for the detection, prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases, including, but not limited to human sarcomas and carcinomas are described. In particular, specific antibodies are provided, which are capable of binding an epitope of Hsp70 that is extracellularly localized on diseased tissue and cells, in particular on tumor cells and infected cells.

Abstract: The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.

Abstract: This invention relates to an antibody which is modified version of a therapeutic antibody with affinity for a cell-surface antigen, the antibody having reduced affinity for the antigen compared with the therapeutic antibody as a result of a modification or modifications to the antibody molecule, wherein the antibody is capable of inducing immunological tolerance to the therapeutic antibody. The invention further relates to a method of inducing immunological tolerance to a therapeutic antibody, comprising administering to a patient an antibody which is a modified version of the therapeutic antibody and which has reduced affinity for the antigen as compared with the therapeutic antibody.

Abstract: The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof.

Abstract: Methods for improving the biological and pharmaceutical properties of bispecific binding agents are described herein where the bispecific binding agents are able to target cells by a high affinity binding domain to a first cell surface marker that does not induce a significant biological effect and a low affinity binding domain that binds specifically to a second cell surface marker, causing a significant and desired biological effect. Compositions of such bispecific binding agents, uses for them, and kits containing them are also provided.

Abstract: The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more bone resorption marker levels, administering a sclerostin binding agent, then measuring the bone resorption marker levels. Also provided is a method of increasing bone mineral density; a method of ameliorating the effects of an osteoclast-related disorder; a method of treating a bone-related disorder by maintaining bone density; and a method of treating a bone-related disorder in a human suffering from or at risk of hypocalcemia or hypercalcemia, a human in which treatment with a parathyroid hormone or analog thereof is contraindicated, or a human in which treatment with a bisphosphonate is contraindicated.

Abstract: Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.

Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.

Abstract: A preventive or therapeutic agent for pancreatitis said agent comprising as an active ingredient an interleukin-6 (IL-6) antagonist such as an antibody directed against IL-6 receptor.

Abstract: The invention provides the identification and characterization of disease and cancer-associated epitope, KID3. The invention also provides a family of monoclonal antibodies that bind to KID3, methods of diagnosing and treating various human cancers and diseases that express KID3.

Abstract: The present invention is related to the field of wound healing or tissue regeneration due to disease (i.e., for example, cardiovascular diseases, osetoarthritic diseases, or diabetes). In particular, the present invention provides compositions and methods comprising molecules with linked ?-gal epitopes for induction of an inflammatory response localized within or surrounding damaged tissue. In some embodiments, the present invention provides treatments for tissue repair in normal subjects and in subjects having impaired healing capabilities, such as diabetic and aged subjects.

Abstract: The current invention provides a method for mobilizing endothelial progenitor cells (EPC) and/or mesenchymal stem cells (MSC) in a patient, wherein the method comprises the steps of (i) administering a vascular endothelial growth factor receptor (VEGFR) agonist to the patient; and (ii) administering an antagonist of CXCR4 to the patient. Also provided are uses of EPC and MSC harvested using the methods of the invention.

Abstract: Methods for desensitization of a mammal suffering from IgE mediated allergy comprise the steps of: administering to said mammal a therapeutically effective amount of an immunogenic and hypoallergenic composition which comprises (i) a Phl p 6 molecule having an N-terminal truncation which makes the molecule at least lack IgE binding capacity, and/or (ii) a Phl p 6 molecule having a C-terminal truncation which makes the molecule at least lack IgE binding capacity, wherein the molecules of (i) and (ii), if employed in combination, together span the complete sequence of Phl p 6, and a pharmaceutically acceptable carrier.

Abstract: An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an ?-helical moiety, or one or more proline residues.

Abstract: The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral vaccine. Another aspect of the inventive subject matter is a method of inducing an immune response against dengue virus using a heterologous prime-boost regimen with the priming immunogen comprising a DNA expression system, an adenovirus expression vector or a Venezuelan equine encephalitis virus replicon system and the boosting immunogen comprising the same without the DNA expression system. Each expression system contains DNA sequences encoding dengue viral proteins.

Abstract: The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate occasions producers are required to assemble the cattle.

Abstract: A novel subtype of type A botulinum neurotoxin (BoNT/A) is disclosed in the application. Methods to purify the neurotoxin as well as uses thereof are also disclosed.

Abstract: Novel vaccines for use against ?-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against ?-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.

Abstract: Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the prevention and/or treatment of tuberculosis are also disclosed.

Abstract: A live bacterium, having a DNA construct stabilized against transduction of other bacteria, having a promoter sequence and encoding a fusion peptide, comprising a bacterial secretion peptide portion and a non-bacterial immunogenic polypeptide portion, having a nucleotide sequence coding for the non-bacterial immunogenic polypeptide portion which has at least one codon optimized for bacterial expression. The bacterium has a secretion mechanism which interacts with at least the bacterial secretion peptide portion to cause a secretion of the fusion peptide from the bacterium, and a genetic virulence attenuating mutation. The bacterium is adapted to act as an animal vaccine, to transiently infect a tissue of the animal, and cause an immunity response to the non-bacterial immunogenic polypeptide portion in the animal to a non-bacterial organism associated with the non-bacterial immunogenic polypeptide portion.

Abstract: The present invention provides Chlamydia proteins and methods of use in diagnostic and detection assays as well as in treatment and immunization protocols.

Abstract: The invention relates to adhesives for medical applications and methods of their preparation and use.

Abstract: Use of an adsorbent and a sealed package (e.g. an overwrap) to protect a pharmaceutical product in a solid state in the presence of a reducing sugar.

Abstract: The invention relates to a composition comprising, in a physiologically acceptable medium, a volatile silicone fatty phase comprising at least one non-cyclic volatile silicone oil, wherein the volatile silicone fatty phase has an evaporation profile such that the mass of the at least one volatile silicone oil evaporated after 30 minutes is from 2 mg/cm2 to 9 mg/cm2. The invention also relates to making up and caring for human keratin materials using the inventive compositions.

Abstract: The present invention relates to treatment of water, and more specifically to treatment of water using a stable formulation of polyhexamethylene biguanide (PHMB) and a liquid or solid zinc salt for the application and prevention algae in recirculated and stagnant water systems. The invention also encompasses methods of treating water that already contains PHMB.

Abstract: Concentrated microemulsions comprising: 1) 10-25 parts by weight of a pesticide with a solubility in water at 20° C. lower than 1% l by weight and having a melting point from 10° C. to 60° C.; 2) 8-25 parts by weight of one or more solvents containing oxygen atoms, having a solubility in water at 20° C. lower than 5% by weight and the Hildebrand solubility parameter in the range 16-21 MPa1/2; 3) 10-20 parts by weight of a polyol; 4) 10-25 parts by weight of one or more non ionic surfactants having a HLB value from 9 to 15; 5) 2-10 parts by weight of one or more anionic surfactants; 6) water up to 100 parts by weight; wherein—the ratio by weight between 2) and 1) ranges from 0.8:1 to 1.5:1;—the ratio by weight between 4) +5) and 1) is in the range 0.5:1-3:1;—the ratio by weight between 4) and 5) ranges from 1:1 to 4.1.